Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Discovery of a Potent and Selective CCR4 Antagonist That Inhibits Treg Trafficking into the Tumor Microenvironment.

Jackson JJ, Ketcham JM, Younai A, Abraham B, Biannic B, Beck HP, Bui MHT, Chian D, Cutler G, Diokno R, Hu DX, Jacobson S, Karbarz E, Kassner PD, Marshall L, McKinnell J, Meleza C, Okal A, Pookot D, Reilly MK, Robles O, Shunatona HP, Talay O, Walker JR, Wadsworth A, Wustrow DJ, Zibinsky M.

J Med Chem. 2019 Jul 11;62(13):6190-6213. doi: 10.1021/acs.jmedchem.9b00506. Epub 2019 Jul 1.

PMID:
31259550
2.

Wnt canonical pathway activates macropinocytosis and lysosomal degradation of extracellular proteins.

Tejeda-Muñoz N, Albrecht LV, Bui MH, De Robertis EM.

Proc Natl Acad Sci U S A. 2019 May 21;116(21):10402-10411. doi: 10.1073/pnas.1903506116. Epub 2019 May 6.

3.

Canonical Wnt is inhibited by targeting one-carbon metabolism through methotrexate or methionine deprivation.

Albrecht LV, Bui MH, De Robertis EM.

Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2987-2995. doi: 10.1073/pnas.1820161116. Epub 2019 Jan 24.

4.

Discovery and optimization of novel constrained pyrrolopyridone BET family inhibitors.

Fidanze SD, Liu D, Mantei RA, Hasvold LA, Pratt JK, Sheppard GS, Wang L, Holms JH, Dai Y, Aguirre A, Bogdan A, Dietrich JD, Marjanovic J, Park CH, Hutchins CW, Lin X, Bui MH, Huang X, Wilcox D, Li L, Wang R, Kovar P, Magoc TJ, Rajaraman G, Albert DH, Shen Y, Kati WM, McDaniel KF.

Bioorg Med Chem Lett. 2018 Jun 1;28(10):1804-1810. doi: 10.1016/j.bmcl.2018.04.020. Epub 2018 Apr 11.

PMID:
29678460
5.

Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor.

McDaniel KF, Wang L, Soltwedel T, Fidanze SD, Hasvold LA, Liu D, Mantei RA, Pratt JK, Sheppard GS, Bui MH, Faivre EJ, Huang X, Li L, Lin X, Wang R, Warder SE, Wilcox D, Albert DH, Magoc TJ, Rajaraman G, Park CH, Hutchins CW, Shen JJ, Edalji RP, Sun CC, Martin R, Gao W, Wong S, Fang G, Elmore SW, Shen Y, Kati WM.

J Med Chem. 2017 Oct 26;60(20):8369-8384. doi: 10.1021/acs.jmedchem.7b00746. Epub 2017 Oct 12.

PMID:
28949521
6.

Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD+ biosynthesis pathway and NAMPT mutation.

Guo J, Lam LT, Longenecker KL, Bui MH, Idler KB, Glaser KB, Wilsbacher JL, Tse C, Pappano WN, Huang TH.

Biochem Biophys Res Commun. 2017 Sep 23;491(3):681-686. doi: 10.1016/j.bbrc.2017.07.143. Epub 2017 Jul 26.

PMID:
28756225
7.

Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies.

Bui MH, Lin X, Albert DH, Li L, Lam LT, Faivre EJ, Warder SE, Huang X, Wilcox D, Donawho CK, Sheppard GS, Wang L, Fidanze S, Pratt JK, Liu D, Hasvold L, Uziel T, Lu X, Kohlhapp F, Fang G, Elmore SW, Rosenberg SH, McDaniel KF, Kati WM, Shen Y.

Cancer Res. 2017 Jun 1;77(11):2976-2989. doi: 10.1158/0008-5472.CAN-16-1793. Epub 2017 Apr 17.

8.

Detection of live circulating tumor cells by a class of near-infrared heptamethine carbocyanine dyes in patients with localized and metastatic prostate cancer.

Shao C, Liao CP, Hu P, Chu CY, Zhang L, Bui MH, Ng CS, Josephson DY, Knudsen B, Tighiouart M, Kim HL, Zhau HE, Chung LW, Wang R, Posadas EM.

PLoS One. 2014 Feb 14;9(2):e88967. doi: 10.1371/journal.pone.0088967. eCollection 2014.

9.

Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.

Glaser KB, Li J, Marcotte PA, Magoc TJ, Guo J, Reuter DR, Tapang P, Wei RQ, Pease LJ, Bui MH, Chen Z, Frey RR, Johnson EF, Osterling DJ, Olson AM, Bouska JJ, Luo Y, Curtin ML, Donawho CK, Michaelides MR, Tse C, Davidsen SK, Albert DH.

J Pharmacol Exp Ther. 2012 Dec;343(3):617-27. doi: 10.1124/jpet.112.197087. Epub 2012 Aug 30.

PMID:
22935731
10.

1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) induces phosphorylation of eukaryotic elongation factor-2 (eEF2): a cautionary note on the anticancer mechanism of an eEF2 kinase inhibitor.

Chen Z, Gopalakrishnan SM, Bui MH, Soni NB, Warrior U, Johnson EF, Donnelly JB, Glaser KB.

J Biol Chem. 2011 Dec 23;286(51):43951-8. doi: 10.1074/jbc.M111.301291. Epub 2011 Oct 21.

12.
13.

Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics.

Tao ZF, Chen Z, Bui MH, Kovar P, Johnson E, Bouska J, Zhang H, Rosenberg S, Sowin T, Lin NH.

Bioorg Med Chem Lett. 2007 Dec 1;17(23):6593-601. Epub 2007 Sep 22.

PMID:
17935989
14.

Discovery of 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-benzonitriles and 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-pyridine-2'-carbonitriles as potent checkpoint kinase 1 (Chk1) inhibitors.

Tao ZF, Li G, Tong Y, Stewart KD, Chen Z, Bui MH, Merta P, Park C, Kovar P, Zhang H, Sham HL, Rosenberg SH, Sowin TJ, Lin NH.

Bioorg Med Chem Lett. 2007 Nov 1;17(21):5944-51. Epub 2007 Aug 25.

PMID:
17827013
15.

Cyanopyridyl containing 1,4-dihydroindeno[1,2-c]pyrazoles as potent checkpoint kinase 1 inhibitors: improving oral biovailability.

Tong Y, Przytulinska M, Tao ZF, Bouska J, Stewart KD, Park C, Li G, Claiborne A, Kovar P, Chen Z, Merta PJ, Bui MH, Olson A, Osterling D, Zhang H, Sham HL, Rosenberg SH, Sowin TJ, Lin NH.

Bioorg Med Chem Lett. 2007 Oct 15;17(20):5665-70. Epub 2007 Aug 21.

PMID:
17768051
16.

Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one-based potent and selective Chk-1 inhibitors.

Wang L, Sullivan GM, Hexamer LA, Hasvold LA, Thalji R, Przytulinska M, Tao ZF, Li G, Chen Z, Xiao Z, Gu WZ, Xue J, Bui MH, Merta P, Kovar P, Bouska JJ, Zhang H, Park C, Stewart KD, Sham HL, Sowin TJ, Rosenberg SH, Lin NH.

J Med Chem. 2007 Aug 23;50(17):4162-76. Epub 2007 Jul 21.

PMID:
17658776
17.
18.

Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors.

Tao ZF, Wang L, Stewart KD, Chen Z, Gu W, Bui MH, Merta P, Zhang H, Kovar P, Johnson E, Park C, Judge R, Rosenberg S, Sowin T, Lin NH.

J Med Chem. 2007 Apr 5;50(7):1514-27. Epub 2007 Mar 13.

PMID:
17352464
19.

Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.

Chen Z, Xiao Z, Gu WZ, Xue J, Bui MH, Kovar P, Li G, Wang G, Tao ZF, Tong Y, Lin NH, Sham HL, Wang JY, Sowin TJ, Rosenberg SH, Zhang H.

Int J Cancer. 2006 Dec 15;119(12):2784-94.

20.

Biomarkers for early detection and optimized treatment for transitional cell carcinoma.

Freedland SJ, Bui MH, Chao D, Pantuck AJ, Zisman A, Belldegrun AS.

Rev Urol. 2001 Fall;3(4):210-2. No abstract available.

21.

Testicular microlithiasis, chemotherapy for stage I seminoma, and chemotherapy for advanced extragonadal germ cell tumors.

Han KR, Wieder JA, Bui MH, Belldegrun AS.

Rev Urol. 2002 Fall;4(4):200-2. No abstract available.

22.

Incidence of ureteral strictures after laparoscopic donor nephrectomy.

Breda A, Bui MH, Liao JC, Gritsch HA, Schulam PG.

J Urol. 2006 Sep;176(3):1065-8.

PMID:
16890691
23.

Synthesis and antibacterial activity of 5-methoxy- and 5-hydroxy-6-fluoro-1,8-naphthyridone-3-carboxylic acid derivatives.

Matthew Hansen T, Gu YG, Rehm TM, Dandliker PJ, Chovan LE, Bui MH, Nilius AM, Beutel BA.

Bioorg Med Chem Lett. 2005 Jun 2;15(11):2716-9.

PMID:
15911248
24.

Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.

Lam JS, Shvarts O, Said JW, Pantuck AJ, Seligson DB, Aldridge ME, Bui MH, Liu X, Horvath S, Figlin RA, Belldegrun AS.

Cancer. 2005 Jun 15;103(12):2517-25.

25.

Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma.

Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, Shi T, Belldegrun AS, Horvath S, Figlin RA.

J Urol. 2005 May;173(5):1496-501.

PMID:
15821467
26.

Using protein expressions to predict survival in clear cell renal carcinoma.

Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, Shi T, Figlin RA, Horvath S, Belldegrun AS.

Clin Cancer Res. 2004 Aug 15;10(16):5464-71.

27.

Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma.

Bui MH, Visapaa H, Seligson D, Kim H, Han KR, Huang Y, Horvath S, Stanbridge EJ, Palotie A, Figlin RA, Belldegrun AS.

J Urol. 2004 Jun;171(6 Pt 1):2461-6.

PMID:
15126876
28.

Synthesis and antibacterial activity of 6-O-arylpropargyl-9-oxime-11,12-carbamate ketolides.

Beebe X, Yang F, Bui MH, Mitten MJ, Ma Z, Nilius AM, Djuric SW.

Bioorg Med Chem Lett. 2004 May 17;14(10):2417-21.

PMID:
15109624
29.

Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma.

Seligson DB, Pantuck AJ, Liu X, Huang Y, Horvath S, Bui MH, Han KR, Correa AJ, Eeva M, Tze S, Belldegrun AS, Figlin RA.

Clin Cancer Res. 2004 Apr 15;10(8):2659-69.

30.

Decreased glutathione in patients with anorexia nervosa. Risk factor for toxic liver injury?

Zenger F, Russmann S, Junker E, Wüthrich C, Bui MH, Lauterburg BH.

Eur J Clin Nutr. 2004 Feb;58(2):238-43.

PMID:
14749742
31.
32.

Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis.

Kim HL, Belldegrun AS, Freitas DG, Bui MH, Han KR, Dorey FJ, Figlin RA.

J Urol. 2003 Nov;170(5):1742-6.

PMID:
14532767
33.

Current staging of renal cell carcinoma.

Leibovich BC, Pantuck AJ, Bui MH, Ryu-Han K, Zisman A, Figlin R, Belldegrun A.

Urol Clin North Am. 2003 Aug;30(3):481-97, viii. Review.

PMID:
12953750
34.

Synthesis and SAR evaluation of oxadiazolopyrazines as selective Haemophilus influenzae antibacterial agents.

Beebe X, Nilius AM, Merta PJ, Soni NB, Bui MH, Wagner R, Beutel BA.

Bioorg Med Chem Lett. 2003 Oct 6;13(19):3133-6.

PMID:
12951079
35.

LABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen.

Zisman A, Pantuck AJ, Bui MH, Said JW, Caliliw RR, Rao N, Shintaku P, Berger F, Gambhir SS, Belldegrun AS.

Cancer Res. 2003 Aug 15;63(16):4952-9.

36.

Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene.

Hernández JM, Bui MH, Han KR, Mukouyama H, Freitas DG, Nguyen D, Caliliw R, Shintaku PI, Paik SH, Tso CL, Figlin RA, Belldegrun AS.

Clin Cancer Res. 2003 May;9(5):1906-16.

37.

PCR-oligonucleotide ligation assay for detection of point mutations associated with quinolone resistance in Streptococcus pneumoniae.

Bui MH, Stone GG, Nilius AM, Almer L, Flamm RK.

Antimicrob Agents Chemother. 2003 Apr;47(4):1456-9.

38.

Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma.

Han KR, Pantuck AJ, Bui MH, Shvarts O, Freitas DG, Zisman A, Leibovich BC, Dorey FJ, Gitlitz BJ, Figlin RA, Belldegrun AS.

Urology. 2003 Feb;61(2):314-9.

PMID:
12597937
39.

TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion.

Han KR, Bui MH, Pantuck AJ, Freitas DG, Leibovich BC, Dorey FJ, Zisman A, Janzen NK, Mukouyama H, Figlin RA, Belldegrun AS.

J Urol. 2003 Mar;169(3):899-903; discussion 903-4.

PMID:
12576809
40.

Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.

Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, Horvath S, Leibovich BC, Chopra S, Liao SY, Stanbridge E, Lerman MI, Palotie A, Figlin RA, Belldegrun AS.

Clin Cancer Res. 2003 Feb;9(2):802-11.

41.

Prognostic factors and molecular markers for renal cell carcinoma.

Bui MH, Zisman A, Pantuck AJ, Han KR, Wieder J, Belldegrun AS.

Expert Rev Anticancer Ther. 2001 Dec;1(4):565-75. Review.

PMID:
12113089
42.

Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus.

Almer LS, Shortridge VD, Nilius AM, Beyer JM, Soni NB, Bui MH, Stone GG, Flamm RK.

Diagn Microbiol Infect Dis. 2002 Jul;43(3):225-32.

PMID:
12106956
43.

Comparative in vitro activity of ABT-773, a novel antibacterial ketolide.

Nilius AM, Bui MH, Almer L, Hensey-Rudloff D, Beyer J, Ma Z, Or YS, Flamm RK.

Antimicrob Agents Chemother. 2001 Jul;45(7):2163-8.

44.

Calyceal diverticula. Ureteroscopic management.

Chong TW, Bui MH, Fuchs GJ.

Urol Clin North Am. 2000 Nov;27(4):647-54. Review.

PMID:
11098763
45.
46.

Anhydrolide macrolides. 2. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbazate erythromycin A analogues.

Griesgraber G, Kramer MJ, Elliott RL, Nilius AM, Ewing PJ, Raney PM, Bui MH, Flamm RK, Chu DT, Plattner JJ, Or YS.

J Med Chem. 1998 May 7;41(10):1660-70.

PMID:
9572891
47.

Anhydrolide macrolides. 1. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbamate erythromycin A analogues.

Elliott RL, Pireh D, Griesgraber G, Nilius AM, Ewing PJ, Bui MH, Raney PM, Flamm RK, Kim K, Henry RF, Chu DT, Plattner JJ, Or YS.

J Med Chem. 1998 May 7;41(10):1651-9.

PMID:
9572890
48.

In situ mitochondrial function in volume overload- and pressure overload-induced cardiac hypertrophy in rats.

Janati-Idrissi R, Besson B, Laplace M, Bui MH.

Basic Res Cardiol. 1995 Jul-Aug;90(4):305-13.

PMID:
8534255
50.

Calculation of the two-photon-annihilation contribution to the positronium hyperfine interval at order m alpha 6.

Adkins GS, Aksu YM, Bui MH.

Phys Rev A. 1993 Apr;47(4):2640-2652. No abstract available.

PMID:
9909234

Supplemental Content

Support Center